Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
BACKGROUND
Multiple myeloma (MM), constantly remains debilitating disease, consequently leading to death. Clinical trials involving drugs with different mechanisms of action, carry the expectancy for improvement of treatment outcomes. The results of the currently published studies on the monoclonal antibodies, in particular elotuzumab confirm previous expectations of improving treatment outcomes of such therapy in MM patients.


METHODS
This humanized monoclonal antibody targeting surface glycoprotein CS1, expressed commonly on plasma cells and certain cells of the immune system, stimulates the immune system to fight against MM cells. Elotuzumab in the combination with len/dex has been approved by the FDA for treatment of relapsed/refractory MM patients who have received one to three prior therapies. Expert commentary: This review summarizes the chemistry, mechanism of action and preclinical and clinical studies, pharmacodynamics, pharmacokinetics, safety and toxicity of elotuzumab in terms of MM treatment and its potential application in the future.
a Department of Cancer Prevention, School of Public Health , Silesian Medical University , Katowice , Poland.
Sebastian
S
Grosicki
b Department of Doctoral Studies, School of Public Health in Bytom , Medical University of Silesia , Katowice , Poland.
Agnieszka
A
Barchnicka
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D016903:Drug Monitoring; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007155:Immunologic Factors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D012008:Recurrence; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007155:Immunologic Factors; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab
Multiple myeloma; efficacy; elotuzumab; immune-stimulating therapy; monoclonal antibody treatment; safety